Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Handok Inc. (002390:KRX), powered by AI.
Handok Inc. is currently trading at ₩8,050. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Handok Inc. on Alpha Lenz.
Handok Inc.'s P/E ratio is -51.5.
“Handok Inc. trades at a P/E of -51.5 (undervalued) with modest ROE of -0.8%.”
Ask for details →Handok Inc. is a prominent player in the pharmaceutical industry, engaged in the development, production, and distribution of a wide range of pharmaceutical products. With its core operations centered in South Korea, Handok Inc. focuses on delivering innovative healthcare solutions that encompass prescription drugs, over-the-counter medicines, and medical devices. The company's diverse product portfolio spans therapeutic areas such as cardiovascular diseases, diabetes, vaccines, and various chronic conditions. Handok Inc. has established itself as a critical component of the healthcare sector, consistently investing in research and development to introduce advanced pharmaceuticals that cater to evolving patient needs and medical standards. The company partners with global and regional firms, leveraging strategic alliances to enhance its market reach and technological capabilities. As a publicly traded company, Handok Inc. plays an essential role in South Korea's healthcare landscape, contributing significantly to the country's pharmaceutical exports and healthcare innovation. Its commitment to quality and efficacy underscores its reputation as a trusted provider of essential healthcare solutions across domestic and international markets.
“Handok Inc. trades at a P/E of -51.5 (undervalued) with modest ROE of -0.8%.”
Ask for details →Handok Inc. (ticker: 002390) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 948 employees. Market cap is $110.8B.
The current price is ₩8,050 with a P/E ratio of -51.46x and P/B of 0.4x.
ROE is -0.76% and operating margin is 0.62%. Annual revenue is $535.1B.